CAM
DRUG

Cormorant Asset Management’s Bright Minds Biosciences DRUG Stock Holding History

Cormorant Asset Management’s Portfolio DRUG Stock Details DRUG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$77.3M Hold
1,059,331
– – 3.88% 11
2025
Q4 		$82.7M Hold
1,059,331
– – 3.82% 10
2025
Q3 		$64.3M Hold
1,059,331
– – 4.43% 7
2025
Q2 		$27.7M Hold
1,059,331
– – 2.06% 14
2025
Q1 		$38.2M Hold
1,059,331
– – 2.87% 10
2024
Q4 		$38.2M Buy
+1,059,331
New +$37.3M 2.1% 13

Other funds holding DRUG

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Cormorant Asset Management's DRUG Position: Q1 2026 in Review

Cormorant Asset Management held its Bright Minds Biosciences (DRUG) position steady in Q1 2026 at 1,059,331 shares worth $77.3M. The position accounts for 3.88% of the portfolio, ranked #11.

Cormorant Asset Management first reported a position in DRUG in Q4 2024 and has held it in 6 quarters since. The position peaked at $82.7M in Q4 2025. 94 funds tracked by Wall St. Rank hold DRUG as of Q1 2026.

  • Cormorant Asset Management held 1,059,331 shares of Bright Minds Biosciences worth $77.3M as of Q1 2026.
  • Cormorant Asset Management left its Bright Minds Biosciences share count unchanged in Q1 2026.
  • Bright Minds Biosciences made up 3.88% of Cormorant Asset Management's portfolio in Q1 2026, its #11 holding.
  • Cormorant Asset Management first reported a position in Bright Minds Biosciences in Q4 2024 and has held it in 6 quarters since.
  • Cormorant Asset Management's Bright Minds Biosciences position peaked at $82.7M in Q4 2025.
  • 94 funds tracked by Wall St. Rank held Bright Minds Biosciences as of Q1 2026.

Based on Cormorant Asset Management's 13F filing for Q1 2026, filed 15 May 2026.